Today a panel of outside experts will examine advise the FDA on whether or not a new injectable version of the popular schizophrenia drug, Zyprexa, should be approved in the US. Zyprexa is currently available in a once-daily pill form, but the new formula, Zyprexa Adhera, can be injected into the muscle and last up to four weeks. The panel will weigh all aspects of the drug and available...